Ovid Therapeutics Inc. (OVID): EBITDA
-$42.17M
Year ended 2025-12-31
-$58.27M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$42.17M | n/m | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | -$61.27M | n/m | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | -$58.71M | n/m | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | -$55.04M | n/m | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | $124.45M | n/m | 2023-03-13, From 2021-01-01 |
| 2020-12-31 | -$81.12M | n/m | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | -$61.15M | n/m | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | -$52.79M | n/m | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | -$64.93M | n/m | 2019-03-07, From 2017-01-01 |
| 2016-12-31 | -$22.48M | n/m | 2018-03-29, From 2016-01-01 |
| 2015-12-31 | -$13.18M | n/a | 2018-03-29, From 2015-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | -$42.17M | n/m |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | -$114.32M | n/m |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | -$370.53M | n/m |
| Immunome Inc. (IMNM) | 2025-12-31 | -$221.65M | n/m |
| Adagene Inc. (ADAG) | 2025-12-31 | -$21.00M | n/m |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | -$34.82M | n/m |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | -$75.92M | n/m |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | -$511.72M | n/m |
| International Stem Cell Corp (ISCO) | 2025-12-31 | -$48.0K | n/m |
Compare OVID, WHWK, XENE, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗